{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T16:52:05Z","timestamp":1784220725530,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T00:00:00Z","timestamp":1546819200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,7]],"date-time":"2019-01-07T00:00:00Z","timestamp":1546819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["CA119053"],"award-info":[{"award-number":["CA119053"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010882","name":"Tianjin Municipal Education Commission","doi-asserted-by":"publisher","award":["20140512"],"award-info":[{"award-number":["20140512"]}],"id":[{"id":"10.13039\/501100010882","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s11307-018-01310-5","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T21:25:34Z","timestamp":1546982734000},"page":"907-916","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["PET Imaging of HER2-Positive Tumors with Cu-64-Labeled Affibody Molecules"],"prefix":"10.1007","volume":"21","author":[{"given":"Shibo","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Hoppmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingding","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8177-9463","authenticated-orcid":false,"given":"Zhen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,7]]},"reference":[{"key":"1310_CR1","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/med.21299","volume":"34","author":"EB Corcoran","year":"2014","unstructured":"Corcoran EB, Hanson RN (2014) Imaging EGFR and HER2 by PET and SPECT: a review. Med Res Rev 34:596\u2013643","journal-title":"Med Res Rev"},{"key":"1310_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2017.06.005","volume":"59","author":"S Parakh","year":"2017","unstructured":"Parakh S, Gan HK, Parslow AC, Burvenich IJG, Burgess AW, Scott AM (2017) Evolution of anti-HER2 therapies for cancer treatment. Cancer Treat Rev 59:1\u201321","journal-title":"Cancer Treat Rev"},{"key":"1310_CR3","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1016\/j.febslet.2010.04.014","volume":"584","author":"J L\u00f6blom","year":"2010","unstructured":"L\u00f6blom J, Feldwisch J, Tolmachev V et al (2010) Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 584:2670\u20132680","journal-title":"FEBS Lett"},{"key":"1310_CR4","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s00726-010-0503-9","volume":"41","author":"Z Miao","year":"2011","unstructured":"Miao Z, Levi J, Cheng Z (2011) Protein scaffold-based molecular probes for cancer molecular imaging. Amino Acids 41:1037\u20131047","journal-title":"Amino Acids"},{"key":"1310_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.trac.2014.10.014","volume":"65","author":"CIL Justino","year":"2015","unstructured":"Justino CIL, Duarte AC, Rocha-Santos TAP (2015) Analytical applications of affibodies. Trac-trend Anal Chem 65:73\u201382","journal-title":"Trac-trend Anal Chem"},{"key":"1310_CR6","first-page":"167","volume":"10","author":"FY Nilsson","year":"2007","unstructured":"Nilsson FY, Tolmachev V (2007) Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Devel 10:167\u2013175","journal-title":"Curr Opin Drug Discov Devel"},{"key":"1310_CR7","doi-asserted-by":"publisher","first-page":"804","DOI":"10.2967\/jnumed.107.047381","volume":"49","author":"Z Cheng","year":"2008","unstructured":"Cheng Z, De Jesus OP, Namavari M et al (2008) Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J Nucl Med 49:804\u2013813","journal-title":"J Nucl Med"},{"key":"1310_CR8","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1158\/1078-0432.CCR-07-4076","volume":"14","author":"SB Lee","year":"2008","unstructured":"Lee SB, Hassan M, Fisher R, Chertov O, Chernomordik V, Kramer-Marek G, Gandjbakhche A, Capala J (2008) Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging. Clin Cancer Res 14:3840\u20133849","journal-title":"Clin Cancer Res"},{"key":"1310_CR9","doi-asserted-by":"publisher","first-page":"6326","DOI":"10.1158\/1078-0432.CCR-06-1732","volume":"12","author":"F Meric-Bernstam","year":"2006","unstructured":"Meric-Bernstam F, Hung MC (2006) Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res 12:6326\u20136330","journal-title":"Clin Cancer Res"},{"key":"1310_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.hoc.2007.03.010","volume":"21","author":"NJ Robert","year":"2007","unstructured":"Robert NJ, Favret AM (2007) HER2-positive advanced breast cancer. Hematol Oncol Clin North Am 21:293\u2013302","journal-title":"Hematol Oncol Clin North Am"},{"key":"1310_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/GCO.0b013e328012980a","volume":"19","author":"G Ferretti","year":"2007","unstructured":"Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F (2007) HER2\/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 19:56\u201362","journal-title":"Curr Opin Obstet Gynecol"},{"key":"1310_CR12","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.tibtech.2017.04.007","volume":"35","author":"S St\u00e5hl","year":"2017","unstructured":"St\u00e5hl S, Gr\u00e4lund T, Karlstr\u00f6m AE et al (2017) Affibody molecules in biotechnological and medical applications. Trends Biotechnol 35:691\u2013712","journal-title":"Trends Biotechnol"},{"key":"1310_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s11307-008-0142-7","volume":"10","author":"M Namavari","year":"2008","unstructured":"Namavari M, Padilla De Jesus O, Cheng Z et al (2008) Direct site-specific radiolabeling of an Affibody protein with 4-[18F]fluorobenzaldehyde via oxime chemistry. Mol Imaging Biol 10:177\u2013181","journal-title":"Mol Imaging Biol"},{"key":"1310_CR14","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1007\/s00259-007-0658-0","volume":"35","author":"G Kramer-Marek","year":"2008","unstructured":"Kramer-Marek G, Kiesewetter DO, Martiniova L, Jagoda E, Lee SB, Capala J (2008) [18F]FBEM-ZHER2:342-Affibody molecule-a new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography. Eur J Nucl Med Mol Imaging 35:1008\u20131018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1310_CR15","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/s00259-011-1879-9","volume":"38","author":"Z Miao","year":"2011","unstructured":"Miao Z, Ren G, Jiang L, Liu H, Webster JM, Zhang R, Namavari M, Gambhir SS, Syud F, Cheng Z (2011) A novel 18F-labeled two-helix scaffold protein for PET imaging of HER2-positive tumor. Eur J Nucl Med Mol Imaging 38:1977\u20131984","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1310_CR16","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1021\/bc400343r","volume":"25","author":"D Rosik","year":"2014","unstructured":"Rosik D, Thibblin A, Antoni G, Honarvar H, Strand J, Selvaraju RK, Altai M, Orlova A, Eriksson Karlstr\u00f6m A, Tolmachev V (2014) Incorporation of a triglutamyl spacer improves the biodistribution of synthetic affibody molecules radiofluorinated at the N-terminus via oxime formation with 18F-4-fluorobenzaldehyde. Bioconjug Chem 25:82\u201392","journal-title":"Bioconjug Chem"},{"key":"1310_CR17","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.7150\/jca.18070","volume":"8","author":"Y Xu","year":"2017","unstructured":"Xu Y, Bai Z, Huang Q, Pan Y, Pan D, Wang L, Yan J, Wang X, Yang R, Yang M (2017) PET of HER2 expression with a novel 18FAl labeled affibody. J Cancer 8:1170\u20131178","journal-title":"J Cancer"},{"key":"1310_CR18","first-page":"512","volume":"47","author":"A Orlova","year":"2006","unstructured":"Orlova A, Nilsson FY, Wikman M et al (2006) Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors. J Nucl Med 47:512\u2013519","journal-title":"J Nucl Med"},{"key":"1310_CR19","doi-asserted-by":"publisher","first-page":"4966","DOI":"10.1021\/jm400218y","volume":"56","author":"C Hofstr\u00f6m","year":"2013","unstructured":"Hofstr\u00f6m C, Altai M, Honarvar H, Strand J, Malmberg J, Hosseinimehr SJ, Orlova A, Gr\u00e4slund T, Tolmachev V (2013) HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [99mTc(CO)3]+-labeled affibody molecules. J Med Chem 56:4966\u20134974","journal-title":"J Med Chem"},{"key":"1310_CR20","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.nucmedbio.2015.02.002","volume":"42","author":"J Zhang","year":"2015","unstructured":"Zhang J, Zhao X, Wang S, Wang N, Han J, Jia L, Ren X (2015) Monitoring therapeutic response of human ovarian cancer to trastuzumab by SPECT imaging with 99mTc-peptide-ZHER2:342. Nucl Med Biol 42:541\u2013546","journal-title":"Nucl Med Biol"},{"key":"1310_CR21","first-page":"846","volume":"47","author":"V Tolmachev","year":"2006","unstructured":"Tolmachev V, Nilsson FY, Widstr\u00f6m C et al (2006) 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 47:846\u2013853","journal-title":"J Nucl Med"},{"key":"1310_CR22","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1021\/bc3002369","volume":"23","author":"A Perols","year":"2012","unstructured":"Perols A, Honarvar H, Strand J, Selvaraju R, Orlova A, Eriksson Karlstr\u00f6m A, Tolmachev V (2012) Influence of DOTA chelator position on biodistribution and targeting properties of 111In-labeled synthetic anti-HER2 affibody molecules. Bioconjug Chem 23:1661\u20131670","journal-title":"Bioconjug Chem"},{"key":"1310_CR23","first-page":"285","volume":"19","author":"MA Fortin","year":"2007","unstructured":"Fortin MA, Orlova A, Malmstrom PU, Tolmachev V (2007) Labelling chemistry and characterization of [90Y\/177Lu]-DOTA-ZHER2:342-3 affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. Int J Mol Med 19:285\u2013291","journal-title":"Int J Mol Med"},{"key":"1310_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nucmedbio.2017.07.003","volume":"54","author":"M Altai","year":"2017","unstructured":"Altai M, Westerlund K, Velletta J, Mitran B, Honarvar H, Karlstr\u00f6m AE (2017) Evaluation of affibody molecule-based PNA-mediated radionuclide pretargeting: development of an optimized conjugation protocol and 177Lu labeling. Nucl Med Biol 54:1\u20139","journal-title":"Nucl Med Biol"},{"key":"1310_CR25","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1158\/0008-5472.CAN-05-3521","volume":"66","author":"A Orlova","year":"2006","unstructured":"Orlova A, Magnusson M, Eriksson TLJ, Nilsson M, Larsson B, H\u00f6id\u00e9n-Guthenberg I, Widstr\u00f6m C, Carlsson J, Tolmachev V, St\u00e5hl S, Nilsson FY (2006) Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 66:4339\u20134348","journal-title":"Cancer Res"},{"key":"1310_CR26","doi-asserted-by":"publisher","first-page":"93","DOI":"10.7150\/thno.12766","volume":"6","author":"H Honarvar","year":"2012","unstructured":"Honarvar H, Westerlund K, Altai M et al (2012) Feasibility of affibody molecule-based PNA-mediated radionuclide pretargeting of malignant tumors. Theranostics 6:93\u2013103","journal-title":"Theranostics"},{"key":"1310_CR27","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s11307-009-0256-6","volume":"12","author":"Z Cheng","year":"2012","unstructured":"Cheng Z, De Jesus OP, Kramer DJ et al (2012) 64Cu-labeled affibody molecules for imaging of HER2 expressing tumors. Mol Imaging Biol 12:316\u2013324","journal-title":"Mol Imaging Biol"},{"key":"1310_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0070028","volume":"8","author":"J Strand","year":"2013","unstructured":"Strand J, Honarvar H, Perols A, Orlova A, Selvaraju RK, Karlstr\u00f6m AE, Tolmachev V (2013) Influence of macrocyclic chelators on the targeting properties of 68Ga-labeled synthetic affibody molecules: comparison with 111In-labeled counterparts. PLoS One 8:e70028","journal-title":"PLoS One"},{"key":"1310_CR29","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s00259-017-3650-3","volume":"44","author":"D Sandberg","year":"2017","unstructured":"Sandberg D, Tolmachev V, Velikyan I, Olofsson H, Wennborg A, Feldwisch J, Carlsson J, Lindman H, S\u00f6rensen J (2017) Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the affibody molecule ABY-025 with PET and SPECT. Eur J Nucl Med Mol Imaging 44:1337\u20131346","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1310_CR30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ejmech.2014.09.082","volume":"87","author":"M Altai","year":"2014","unstructured":"Altai M, Honarvar H, W\u00e5llberg H, Strand J, Varasteh Z, Rosestedt M, Orlova A, Dun\u00e5s F, Sandstr\u00f6m M, L\u00f6fblom J, Tolmachev V, St\u00e5hl S (2014) Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with 188Re. Eur J Med Chem 87:519\u2013528","journal-title":"Eur J Med Chem"},{"key":"1310_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.nucmedbio.2016.10.004","volume":"45","author":"H Honarvar","year":"2017","unstructured":"Honarvar H, M\u00fcller C, Cohrs S, Haller S, Westerlund K, Karlstr\u00f6m AE, van der Meulen NP, Schibli R, Tolmachev V (2017) Evaluation of the first 44Sc-labeled affibody molecule for imaging of HER2-expressing tumors. Nucl Med Biol 45:15\u201321","journal-title":"Nucl Med Biol"},{"key":"1310_CR32","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/cbic.200900062","volume":"10","author":"JM Webster","year":"2009","unstructured":"Webster JM, Zhang R, Gambhir SS, Cheng Z, Syud FA (2009) Engineered two-helix small proteins for molecular recognition. Chembiochem 10:1293\u20131296","journal-title":"Chembiochem"},{"key":"1310_CR33","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1021\/bc200596a","volume":"23","author":"S Qi","year":"2012","unstructured":"Qi S, Miao Z, Liu H, Xu Y, Feng Y, Cheng Z (2012) Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors. Bioconjug Chem 23:1149\u20131156","journal-title":"Bioconjug Chem"},{"key":"1310_CR34","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1101\/gad.1047403","volume":"17","author":"TF Massoud","year":"2013","unstructured":"Massoud TF, Gambhir SS (2013) Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev 17:545\u2013580","journal-title":"Genes Dev"},{"key":"1310_CR35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1021\/bc700307y","volume":"19","author":"S Ahlgren","year":"2008","unstructured":"Ahlgren S, Orlova A, Rosik D, Sandstr\u00f6m M, Sj\u00f6berg A, Baastrup B, Widmark O, Fant G, Feldwisch J, Tolmachev V (2008) Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. Bioconjug Chem 19:235\u2013243","journal-title":"Bioconjug Chem"},{"key":"1310_CR36","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0969-8051(96)00130-8","volume":"23","author":"PJ Blower","year":"1996","unstructured":"Blower PJ, Lewis JS, Zweit J (1996) Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol 23:957\u2013980","journal-title":"Nucl Med Biol"},{"key":"1310_CR37","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1021\/ar800255q","volume":"42","author":"M Shokeen","year":"2009","unstructured":"Shokeen M, Anderson CJ (2009) Molecular imaging of cancer with copper-64 raidiopharmaceuticals and positron emission tomography (PET). Accounts Chem Res 42:832\u2013841","journal-title":"Accounts Chem Res"},{"key":"1310_CR38","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1002\/jlcr.3165","volume":"57","author":"Z Cai","year":"2013","unstructured":"Cai Z, Anderson CJ (2013) Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals. J Label Compd Radiopharm 57:224\u2013230","journal-title":"J Label Compd Radiopharm"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-018-01310-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11307-018-01310-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-018-01310-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T21:19:26Z","timestamp":1589663966000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11307-018-01310-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,7]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["1310"],"URL":"https:\/\/doi.org\/10.1007\/s11307-018-01310-5","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,7]]},"assertion":[{"value":"7 January 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal studies were performed based on the protocol approved by the Stanford University Administrative Panels on Laboratory Animal Care (APLAC).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}